TABLE 1.

General characteristics of the included randomised control trials for this network meta-analyses (Abbreviations: MN,multinational; NA, not applicable.)

First author, year	Study ID	Region	Trial phase	Trail number	Experimental group	Control group
Carbone 2017	Checkmate 026	MN	II	423	Nivolumab 3 mg/kg	Platinum-based chemotherapy
Naiyer 2020	Mystic	MN	III	721	Durvalumab 20 mg/kg	Platinum-based chemotherapy
Paz-Ares 2018	Keynote-407	United States	III	559	Pembrolizumab 200 mg + platinum-based chemotherapy	Platinum-based chemotherapy
Gandhi 2018	Keynote-189	MN	III	616	Pembrolizumab 200 mg + platinum-based chemotherapy	Platinum-based chemotherapy
Mok 2019	Keynote-042	MN	III	1,274	Pembrolizumab 200 mg	Platinum-based chemotherapy
Reck 2019	Keynote-024	MN	III	305	Pembrolizumab 200 mg	Platinum-based chemotherapy
Borghaei 2016	Keynote-021	United States, Taiwan	I/II	123	Pembrolizumab 200 mg + platinum-based Chemotherapy	Platinum-based chemotherapy
Rivero 2018	Impower 132	MN	Ⅲ	578	Atezolizumab 1200 mg + platinum-based Chemotherapy	Platinum-based chemotherapy
Robert 2018	Impower 131	MN	Ⅲ	1,021	Atezolizumab 1200 mg + platinum-based Chemotherapy	Platinum-based chemotherapy
West 2019	Impower 130	MN	Ⅲ	724	Atezolizumab 1200 mg + platinum-based Chemotherapy	Platinum-based chemotherapy
Spigel 2019	Impower 110	MN	III	572	Atezolizumab 1200 mg	Platinum-based chemotherapy
Hellmann 2018	Checkmate 227	MN	III	1,537	Nivolumab 3 mg/kg Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg	Platinum-based chemotherapy